Neovasc, an OPKO Supported Company, Reports That Reducer Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with

07-11-2013 Business Wire HealthComments (0)


OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Neovasc Inc. (NVC.V), a Vancouver-based company in which OPKO has made a strategic investment, reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the sympt

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top